Ramsay Health Care (RMY) AI Stock Analysis

Ramsay Health Care

(BX Swiss:RMY)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Underlying earnings growthBroad revenue and EBIT growth indicates continued demand for Ramsay’s hospital services and improving operating leverage. Sustained earnings expansion across the group can strengthen internal funding capacity and support investment in facilities and technology.

Negative Factors

Leverage and earnings volatilityA highly leveraged balance sheet limits financial flexibility, particularly when profitability is uneven. Volatile earnings and shareholder returns make deleveraging less predictable and could constrain acquisitions, dividends or investment during weaker operating periods.

Ramsay Health Care Business Overview & Revenue Model

Company Description

Ramsay Health Care Limited is a prominent healthcare provider that manages and possesses hospitals. The company delivers medical services to both publicly funded and privately insured individuals. It maintains a substantial international presence, op...

Ramsay Health Care Earnings Call Summary

Earnings Call Date:Aug 25, 2026(Q4-2026)|Next Earnings Date:Mar 02, 2027

Earnings Call SentimentPositive

The call presents strong operational and financial momentum driven by Australian transformation initiatives and Funding Group improvements — evidenced by double-digit underlying EBIT growth in Australia, broad regional EBIT growth, improved margins and cash generation, higher dividends, and successful cost and utilization measures. Offsetting these positives are notable challenges in Europe (Ramsay Santé funding headwinds and working capital/timing issues), restructure costs and demand weakness at Elysium, wage inflation pressures from multi-year EBAs, a remediation provision relating to a Fair Work decision, and increased interest costs. On balance the company demonstrates tangible progress on its strategic priorities and financial discipline while managing several region-specific headwinds.

Positive Updates

Group Revenue and Profit Growth

Total revenue of $18.6 billion, up 4.2% year-over-year in constant currency; underlying EBIT increased 11.8% and underlying NPAT increased 22.9%; reported NPAT was $329 million.

Negative Updates

Ramsay Santé Funding and Working Capital Headwinds

Ramsay Santé faced a difficult funding environment in France leading to a reduced underlying loss in Europe; negative working capital variance driven by timing of payments from the French government; bank leverage at Ramsay Santé 4.7x at 30 June and business remains loss-making at group level.

Company Guidance

The company guided to continued EBIT growth across Australia and the U.K. in FY‑27, with Australia targeting incremental year‑on‑year EBIT growth (both including and excluding the $251m National Capital acquisition) and margin expansion while investing an incremental $10–15m of IT/technology OpEx; NatCap is expected to be EPS‑accretive in year one with transition operating costs of $9–11m and Australia CapEx of $380–410m (inclusive of NatCap) and 11 new theatres/cath labs planned. At the Funding Group level FY‑27 CapEx is guided to $480–520m, total net interest costs (including AASB‑16) to $280–300m with a weighted average cost of debt of ~5.5% and ~60% of debt hedged, and leverage (1.83x at June 30) expected to remain below the 2.5x target range post‑acquisition (interest cover 8.94x); management also confirmed continued focus on cash generation, ROCE improvement and that Ramsay Santé separation remains on track for late‑2026 (shareholder vote 24 Nov) with an Investor Day on 30 Nov.

Ramsay Health Care Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:RMY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:SHL	72Outperform	AUD 9.67B	15.85	7.20%	5.51%	14.40%	15.11%
AU:REG	57Neutral	AUD 1.45B	26.25	-264.68%	3.79%	16.55%	13.42%
AU:ACL	54Neutral	AUD 615.51M	26.05	15.80%	4.02%	-0.90%	-25.09%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:HLS	51Neutral	AUD 359.46M	-0.88	-114.08%	―	2.16%	21.05%
AU:IDX	48Neutral	AUD 659.20M	29.59	3.24%	5.28%	25.73%	390.83%

* Healthcare Sector Average

Performance Comparison

CH:RMY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
AU:HLS	Healius Limited	0.51	-0.36	-41.71%
AU:REG	Regis Healthcare Ltd.	4.86	-2.36	-32.71%
AU:SHL	Sonic Healthcare Limited	19.59	-0.14	-0.71%
AU:IDX	Integral Diagnostics Ltd.	1.76	-0.76	-30.08%
AU:ACL	Australian Clinical Labs Ltd	3.23	0.68	26.87%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Ramsay Health Care AI Stock Analysis